Table 2

Summary estimates for change in DAS28-CRP (primary outcome measure) over 12 months

RLCNLCDifference*
Mean (SD)Mean (SD)Mean (95% CI)
Week 6
 PP−1.37 (1.27)−0.95 (1.25)−0.15 (−0.41 to 0.11)
 ITT−1.35 (1.21)−0.97 (1.22)−0.17 (−0.41 to 0.06)
Week 12
 PP−1.54 (1.21)−1.31 (1.40)−0.03 (−0.29 to 0.23)
 ITT−1.53 (1.53)−1.34 (1.40)−0.09 (−0.31 to 0.13)
Week 24
 PP−1.58 (1.4)−1.46 (1.59)−0.04 (−0.29 to 0.21)
 ITT−1.56 (1.37)−1.48 (1.57)−0.02 (−0.23 to 0.19)
Week 36
 PP−1.71 (1.34)−1.58 (1.50)−0.03 (−0.30 to 0.24)
 ITT−1.44 (1.20)−1.26 (1.27)−0.08 (−0.30 to 0.15)
Week 52
 PP−1.84 (1.28)−1.87 (1.35)0.02 (−0.23 to 0.27)
 ITT−1.86 (1.20)−1.87 (1.32)0.02 (−0.19 to 0.19)
Average
 PP−1.61 (1.30)−1.43 (1.42)−0.05 (−0.30 to 0.21)
 ITT−1.55 (1.30)−1.38 (1.36)−0.07 (−0.29 to 0.14)
  • Analysis of complete cases (number of DAS28-CRP responders: RLC group and NLC group).

  • Primary endpoint evaluation.

  • *Difference in mean DAS28-CRP change scores for the RLC group minus the NLC group (adjusted for centre).

  • DAS28-CRP, Disease Activity Score in 28 Joints measured with C reactive protein; ITT, intention to treat; NLC, nurse-led care; PP, per protocol; RLC, rheumatologist-led care.